Abstract
In the present work we described improvements in the 1-7 antiparasitic Morita-Baylis-Hillman Adducts synthesis and their antimitotic activity on sea urchin embryonic cells. The 2-[Hydroxy(2-nitrophenyl)methyl]acrylonitrile (1) and 2-[Hydroxy(4-bromophenyl) methyl]acrylonitrile (4) were the most effective compounds to block the progression to embryonic morula stage (EC50 = 75.8 M and 72.6 M, respectively). Compounds 1 and 4 were also effective in blocking the first cell division but to a lesser extent. The 2-[Hydroxy(pyridin-4-yl)methyl]acrylonitrile (7) exhibited a strong inhibition of cell divisions and progression to the first cleavage and morula stage. Fluorescent dye extrusion assay suggests that these adducts are not ABC protein substrates, which confers an additional interest in these new class of potential anticancer drugs.
Keywords: Antimitotic activities, Sea-urchin embryonic cells, Morita-Baylis-Hillman adducts, Cancer
Medicinal Chemistry
Title:Antimitotic Activity on Sea Urchin Embryonic Cells of Seven Antiparasitic Morita-Baylis-Hillman Adducts: A Potential New Class of Anticancer Drugs
Volume: 8 Issue: 6
Author(s): Jocelmo C. A. Leite, Claudio G. L. Junior, Fabio P. L. Silva, Suervy C.O. Sousa, Mario L. A. A. Vasconcellos and Luis F. Marques-Santos
Affiliation:
Keywords: Antimitotic activities, Sea-urchin embryonic cells, Morita-Baylis-Hillman adducts, Cancer
Abstract: In the present work we described improvements in the 1-7 antiparasitic Morita-Baylis-Hillman Adducts synthesis and their antimitotic activity on sea urchin embryonic cells. The 2-[Hydroxy(2-nitrophenyl)methyl]acrylonitrile (1) and 2-[Hydroxy(4-bromophenyl) methyl]acrylonitrile (4) were the most effective compounds to block the progression to embryonic morula stage (EC50 = 75.8 M and 72.6 M, respectively). Compounds 1 and 4 were also effective in blocking the first cell division but to a lesser extent. The 2-[Hydroxy(pyridin-4-yl)methyl]acrylonitrile (7) exhibited a strong inhibition of cell divisions and progression to the first cleavage and morula stage. Fluorescent dye extrusion assay suggests that these adducts are not ABC protein substrates, which confers an additional interest in these new class of potential anticancer drugs.
Export Options
About this article
Cite this article as:
C. A. Leite Jocelmo, G. L. Junior Claudio, P. L. Silva Fabio, C.O. Sousa Suervy, L. A. A. Vasconcellos Mario and F. Marques-Santos Luis, Antimitotic Activity on Sea Urchin Embryonic Cells of Seven Antiparasitic Morita-Baylis-Hillman Adducts: A Potential New Class of Anticancer Drugs, Medicinal Chemistry 2012; 8 (6) . https://dx.doi.org/10.2174/1573406411208061003
DOI https://dx.doi.org/10.2174/1573406411208061003 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cytotoxic Effects of Chemotherapeutic Drugs and Heterocyclic Compounds at Application on the Cells of Primary Culture of Neuroepithelium Tumors
Medicinal Chemistry Foods for Health and to Treat Diseases
Current Pediatric Reviews Signal Transducer and Activator of Transcription 5 (STAT5), a Crucial Regulator of Immune and Cancer Cells
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Determination of Vulpinic Acid Effect on Apoptosis and mRNA Expression Levels in Breast Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Genes for Anti-HIV/AIDS Gene Therapy
Current Pharmaceutical Biotechnology Advances in Clinical Study of Curcumin
Current Pharmaceutical Design Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry Studying Interactions of Drugs with Cell Membrane Nutrient Transporters: New Frontiers of Proteoliposome Nanotechnology
Current Pharmaceutical Design Development and Validation of a Highly Sensitive HPLC Method for Determination of Paclitaxel in Pharmaceutical Dosage forms and Biological Samples
Current Pharmaceutical Analysis Evaluation of the Anthelmentic Activity of Garlic (Allium sativum) in Mice Naturally Infected with Aspiculuris tetraptera
Recent Patents on Anti-Infective Drug Discovery Adenosine Analogues as Opposite Modulators of the Cisplatin Resistance of Ovarian Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Angiotensin II Type 1 Receptor Antagonist as an Angiogenic Inhibitor in Urogenital Cancer
Reviews on Recent Clinical Trials Peripheral Mononuclear Cell Rejuvenation for Senescence Surveillance in Alzheimer Disease
Current Pharmaceutical Design Fyn Kinase in Brain Diseases and Cancer: The Search for Inhibitors
Current Medicinal Chemistry Genistein Decreases APP/tau Phosphorylation and Ameliorates Aβ Overproduction Through Inhibiting CIP2A
Current Alzheimer Research Bioinformatic Approaches in Glycomics and Glycoproteomics
Current Proteomics Nitric Oxide: Cancer Target or Anticancer Agent?
Current Cancer Drug Targets Histone Deacetylase Inhibitors as Potential Therapeutic Agents for the Treatment of Malignant Mesothelioma
Anti-Cancer Agents in Medicinal Chemistry Combining Drug-Loaded Nanobubbles and Extracorporeal Shock Waves for Difficult-to-Treat Cancers
Current Drug Delivery Overcoming the Drug Resistance Problem with Second-Generation Tyrosine Kinase Inhibitors: From Enzymology to Structural Models
Current Medicinal Chemistry